Updated Recommendations From the 2024 International Antiviral Society-USA Panel

Following the US Food and Drug Administration approval of lenacapavir for HIV preexposure prophylaxis (PrEP) on June 18, 2025, and the release of new data on the use of tenofovir alafenamide/emtricitabine among cisgender women, the International Antiviral Society-USA (IAS-USA) panel submitted brief update of its 2024 special recommendations for HIV prevention to the Journal of the American Medical Association, which was published on June 27, 2025.

The updated recommendations can be found through the button below.